428 results on '"Juliusson, Gunnar"'
Search Results
2. First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
3. High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
4. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
5. Cytarabine dose intensification improves survival in older patients with secondary/high-risk acute myeloid leukemia in matched real-world versus clinical trial data
6. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia
7. Epidemiology and Etiology of AML
8. Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture‐Based Gene Panel.
9. Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century
10. Hairy cell leukemia and COVID-19 adaptation of treatment guidelines
11. Pharmacokinetics of Purine Nucleoside Analogs
12. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
13. Epidemiology and Etiology of AML
14. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial
15. Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting
16. P513: MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY FROM THE SWEDISH AML REGISTRY.
17. P432: VALIDATION OF LIMIT OF QUANTIFICATION APPROACH BASED FLOW CYTOMETRY FOR MEASURABLE RESIDUAL DISEASE ASSESSMENT IN ACUTE MYELOID LEUKEMIA IN THE HOVON-SAKK-132 TRIAL
18. P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.
19. Hairy cell leukemia variant and WHO classification correspondence Re: 5thedition WHO classification haematolymphoid tumors: lymphoid neoplasms
20. Clonal competition within complex evolutionary hierarchies shapes AML over time
21. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia
22. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
23. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
24. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
25. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
26. Figure S2B from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
27. Table S1 from Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
28. Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification
29. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations
30. Characterization of therapy-related acute myeloid leukemia : increasing incidence and prognostic implications
31. Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology
32. The complement receptor C3AR constitutes a novel therapeutic target in NPM1-mutated AML
33. Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements
34. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
35. Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching
36. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis
37. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
38. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia
39. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study
40. Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
41. Targeting SAMHD1 with hydroxyurea in first‐line cytarabine‐based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT‐AML trial
42. Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia
43. A risk score based on real-world data to predict early death in acute promyelocytic leukemia
44. Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population‐based data from the Swedish Myeloma Register
45. Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification
46. Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study
47. A risk score based on real-world data to predict early death in acute promyelocytic leukemia
48. Leukemia
49. Combinatorial molecule screening identified a novel diterpene and the BET inhibitor CPI-203 as differentiation inducers of primary acute myeloid leukemia cells
50. A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.